Sierra Oncology — Merger or Acquisition (April 2022)
17 slides from Sierra Oncology's merger presentation, Apr 13, 2022
Slide 1: GSK announces proposed acquisition of Sierra Oncology
CKe ®Nows fr investors and Himoclos We've announced the proposed acquisition of Sierra Oncology, a late-stage, cancer focused biopharma, company, that strengthens our portfolio of specialty medicines and lmportant additonal info available at: 29% 19/3) ‘Advancing our lat- stage pipeline
Slide 2: Announced proposed acquisition of Sierra Oncology
s and #medie: We've announced the proposed ‘acquisition of 2s 2rraonco logy, a late-stage, cancer-focused biopharma ‘company, that strengthens our portfolio of specialty modicines and vaccines. Important additional info available at: i o/3iv2mIM Advancing our late-stage pipeline
Slide 3: Internal communication made to GSK employees
The following is an internal communication made to GSK employees:
Slide 4: Copy of GSK investor relations deck distributed April 13, 2022
The following is a copy of the GSK investor relations deck distributed on April 13, 2022:
Slide 5: Agreement to acquire Sierra Oncology, Inc.
13 April 2022 Agreement to acquire late-stage biopharmaceutical company Sierra Oncology, Inc. Expanding GSK’s haematology portfolio with a late-stage potential new medicine for myelofibrosis patients with anaemia
Slide 6: Additional information and where to find it
Additional information and where to find It This communication is being made in respect of the proposed acquisition of Sierra Oncology, Inc. (“Sierra”) by GlaxoSmithKline plc (“GSK”). In connection with the proposed acquisition, Sierra intends to file with the Securities and Exchange Commission (the
Slide 7: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.
Slide 8: Speakers
Speakers Luke Miels Chief Commercial Officer Nina Mojas SVP, Global Product Strategy, Oncology Hesham Abdullah SVP, Global Head of Development, Oncology
Slide 9: Acquisition of late-stage biopharmaceutical company Sierra Oncology Inc.
Acquisition of late-stage biopharmaceutical company Sierra Oncology Inc. Momelotinib has the potential to address the critical unmet medical needs of myelofibrosis patients with anaemia Strategic rationale Aligns with GSK’s strategy of building a strong portfolio of new specialty medicines and vacci
Slide 10: Myelofibrosis is a fatal cancer of the bone marrow
Myelofibrosis is a fatal cancer of the bone marrow affecting c.20k US patients Median survival is typically between four to six years Source: GSK 1. Outside of transplant. Cytopenia Splenomegaly Constitutional symptoms Progressive bone marrow fibrosis due to inflammation Degraded marrow function Dec
Slide 11: Anaemia is intrinsic to myelofibrosis
Anaemia is intrinsic to myelofibrosis Current treatment options typically exacerbate anaemia Transfusion is an independent prognostic factor of overall survival in myelofibrosis1 Anaemia is frequent in newly diagnosed patients, worsening with disease progression Source: Baseline population in SIMPLI
Slide 12: Momelotinib inhibits ACVR1 / ALK2, JAK1, and JAK2
Momelotinib inhibits ACVR1 / ALK2, JAK 1, and JAK2 Source: Sierra Oncology, Inc., Delivering Transformative Therapies for Rare Cancers, January 2022. Momelotinib impacts all three disease drivers of myelofibrosis – anaemia, spleen, and symptoms Spleen and symptoms potentially result from hyperactive
Slide 13: Momelotinib MOMENTUM phase III trial
Momelotinib MOMENTUM phase III trial Met all pre-specified primary and key secondary endpoints MOMENTUM phase III Demonstrated statistical significance in primary and key secondary endpoints in a difficult to treat patient population High-level results showed a clinically meaningful benefit in anaem
Slide 14: Q&A
Q&A
Slide 15: Appendix
Appendix
Slide 16: Anaemia in myelofibrosis is a significant unmet medical need
Reasons potentially include Patients not yet on JAK inhibitor therapy; may be on watch-and-wait Top-3 reasons for discontinuation Anaemia Thrombocytopenia Disease progression (some may get fedratinib) Reasons for receiving sub-therapeutic dose Anaemia Reasons potentially include Severe thrombocytope
Slide 17: Positioning of momelotinib in the treatment algorithm
Positioning of momelotinib in the treatment algorithm Source: Company analysis. Diagnosis Intermediate or high-risk myelofibrosis HCT eligible Hematopoietic cell transplant (HCT) ineligible Platelet count <50*109 / L Platelet count ≥50*109 / L Platelet count ≥50*109 / L Platelet count ≥50*109 / L Sy